Skip to content Skip to navigation

Incomplete vitreomacular traction release using intravitreal ocriplasmin.

TitleIncomplete vitreomacular traction release using intravitreal ocriplasmin.
Publication TypeJournal Article
Year of Publication2014
AuthorsChin, Eric K., Almeida David R. P., Sohn Elliott H., H Boldt Culver, Mahajan Vinit B., Gehrs Karen M., Russell Stephen R., and Folk James C.
JournalCase Rep Ophthalmol
Date Published2014 Sep-Dec

PURPOSE: To report the clinical course of our first 7 consecutive patients treated with intravitreal ocriplasmin (Jetrea(®)).

METHODS: Retrospective case series of the first 7 patients treated with ocriplasmin between January and December 2013 at an academic tertiary care center.

RESULTS: The average age was 78.4 years (range: 63-92). Five patients were pseudophakic and 2 patients were phakic in the injected eye. The median baseline visual acuity (VA) was 20/60 (range: 20/25 to 20/200). The median 1-month postinjection VA was 20/70, with a mean loss of 2 lines of VA among all patients. None of the patients had complete resolution of their vitreomacular traction or macular hole at 1 month of follow-up. Three patients had subsequent pars plana vitrectomy and membrane peeling surgery. The mean follow-up period for those who did not undergo vitrectomy was 9 months (range: 1-13). One patient with known ocular hypertension had an increase in intraocular pressure requiring topical pressure-lowering eyedrops. There were no cases of postinjection uveitis, endophthalmitis, retinal tears, or retinal detachment.

CONCLUSIONS: While ocriplasmin may be a viable pharmacological agent for vitreolysis, we present a series of patients that all had incomplete resolution of vitreomacular traction with and without full-thickness macular hole. There was an associated reduction in VA after ocriplasmin treatment at 1 month of follow-up. Careful analysis of the vitreoretinal interface and comorbid eye conditions is required to optimize outcome success with ocriplasmin.

Alternate JournalCase Rep Ophthalmol
PubMed ID25606039
PubMed Central IDPMC4296250